Biotech Startups

Proviera develops probiotic-based chemical treatments for leather manufacturing that reduce reliance on conventional chemicals while maintaining process efficiency. The products are designed for tanners and leather processors seeking sustainable alternatives with lower environmental impact.

1 investor

Provigate develops a low/non-invasive, low-cost home glucose monitoring service based on weekly glycated albumin (GA) testing from finger-prick blood or saliva samples via mail-in and point-of-care testing, paired with a coaching app and a remote monitoring dashboard for clinicians. It targets people with diabetes and those at risk, aiming to support behavior change for blood-sugar management.

1 investor

Proxima Bio is an early-stage biotechnology company developing protein degradation technology to target previously undruggable proteins for treatment of autoimmune conditions and cancers. The company is spun out of WEHI (Walter and Eliza Hall Institute) and based in Melbourne, Australia.

1 investor

Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.

1 investor

Psigryph develops Nanopect, a patented plant-derived nanodelivery system that transports bioactive molecules (nutrients, cannabinoids, pharmaceuticals) across cell membranes of plants, animals, and humans to increase bioavailability. The technology, derived from Montmorency sour cherries, targets industries including food and beverage, agriculture, pharmaceutical, and cannabis.

1 investor

PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options. It combines clinical and scientific expertise to bring these treatments to patients worldwide.

1 investor

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system. The company pursues its own drug pipeline and partnerships with pharmaceutical companies across drug classes.

1 investor

Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations. The company is advancing PUL-042, a patent-protected therapy being evaluated in clinical trials.

1 investor

Puna Bio develops agricultural inputs using extremophile microorganisms from the Argentine Puna to promote sustainable farming practices. The company applies nature-based biotechnology solutions to improve agricultural productivity while supporting environmental stewardship.

1 investor

1 investor

Pure Algae develops land-based seaweed cultivation systems that capture nitrogen and CO2 from industrial fish farming and convert them into valuable biomass. The company serves aquaculture facilities seeking to add profitable revenue streams while reducing environmental impacts.

1 investor

Pure MHC discovers HLA Class I and Class II peptide targets for immunotherapies targeting cancer, infectious disease, and autoimmune diseases using the sHLA platform technology.

1 investor

Purgo Scientific develops localized drug delivery medical devices designed to deliver therapeutics to specific anatomical sites. The company serves clinical markets including orthopedic trauma and veterinary medicine, with commercialized veterinary products and human clinical development underway.

1 investor

Purna provides contract development and manufacturing services for pharmaceutical projects, focusing on long-term customer partnerships and operational flexibility to meet customized client needs.

1 investor

1 investor

Pyrojas develops whole-cell cancer vaccines engineered from patients' own tumors to activate T cell responses against multiple antigens. The company focuses on precision immunotherapy for cancer treatment.

1 investor

Q-Sera is a biotech company backed by Australian investors Uniseed and Brandon BioCatalyst, emerging from University of Queensland commercialisation efforts.

1 investor

QCDx develops liquid biopsy technologies using live 3D imaging to detect and profile circulating tumor cells for cancer diagnosis and drug development. The RareScope platform enables oncologists to optimize treatment strategies and therapeutic agents through single-cell phenotypic analysis of rare cancer cells in early-stage and advanced disease.

1 investor

QED Science develops AI tools designed to assist human scientists in their research rather than replace them, trained on feedback from thousands of domain experts including Nobel laureates. It serves scientists and research organizations, with offerings aimed at pharma, biotech, and life science organizations.

1 investor

Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions. Its lead candidate, QLS-111, is a topical eye-drop treatment for glaucoma that lowers intraocular pressure by targeting episcleral venous pressure.

1 investor

Qlucore develops software for exploring and analyzing high-dimensional biological data, including gene expression and next-generation sequencing data, through interactive 3D visualization and machine learning. Founded out of Lund University research, it also offers a platform for multi-omics companion and precision diagnostics aimed at precision oncology and clinical use.

1 investor

Qnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.

1 investor

QNTM Labs is a GMP-certified contract laboratory providing quality control testing and chemical analysis services for pharmaceutical companies, with particular expertise in small molecule drugs. The company offers outsourced QC activities, analytical method development, stability studies, and trace element analysis to help pharmaceutical manufacturers meet regulatory compliance and quality standards.

1 investor

Qorium develops cell-cultured leather grown from a single animal cell sample, producing uniform collagen sheets that integrate into existing tannery and leather-goods production processes. It partners with tanneries and global brands to supply real leather for luxury products such as bags, automotive interiors, and footwear without slaughtering animals.

1 investor